Repurposing of IL 33/ST2 Modulating Drugs as a Cardioprotective Agent: A Promising Approach

Drug repurposing has emerged as an enigmatic clinical approach in disorders affecting the cardiovascular system. The concept of drug repurposing has become feasible due to an interim in performing trials for new entities in cardiovascular diseases (CVDs) rather than cancer and diabetes. One of the naïve pathologies brought to the forefront was IL-33/ST2. After delving deeply into this pathway, mitigated levels of sST2 (a decoy receptor for IL-33) were found to prevent plaque formation and fibrosis. This novelty demands the identification of novel therapeutic targets. In this study, the chronopharmacology of frequently prescribed conventional cardiovascular medications was evaluated, and a hypothesis on β-blockers and mineralocorticoid receptor antagonists in modulating the IL-33/ST2 pathway was proposed for their ability to upregulate IL-33, which specifically exhibits cardioprotective activity. This future perspective advocates precise influences in aiming for IL-33 as a key factor for repurposing these medications in CVDs that reduce inflammation and help to unravel potential cardioprotective action and promising outcomes.